Consano Bio is a clinical-stage biotechnology company developing multi-protein biologic therapeutics for serious, painful orthopedic conditions. Its lead program, C-1101, is a potential first-in-class, non-opioid, disease-modifying therapy for chronic lumbosacral radiculopathy (chronic sciatica), delivered by epidural injection to modulate inflammation and stimulate cellular repair at the site of nerve injury. Headquartered in Burlington, Massachusetts, the company is running a Phase 1 trial of C-1101 in Australia and the United States and received FDA Fast Track designation for the candidate in August 2026.
1
Round
1
Industry
5
Tags
Oct 5, 2026
Latest raise
Funding activity · 1 round
Oct 5, 2026
$15M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
